+1 (662) 727-5061
+1 (662) 727-5061
info@telcapharmacy.org
Telcapharmacy

Product Details

OPDIVO. buy OPDIVO online
  • OPDIVO. buy OPDIVO online

OPDIVO. buy OPDIVO online

$1000

Opdivo (nivolumab) is a cancer medicine that is used alone or in combination with other medicines that works with your immune system to interfere w...

TOP DRUGS

In stock

Opdivo (nivolumab) is a cancer medicine that is used alone or in combination with other medicines that works with your immune system to interfere with the growth and spread of cancer cells in the body.
Opdivo may be used to treat:

advanced skin cancer (melanoma);

lung cancer;

kidney cancer;

classical Hodgkin lymphoma;

squamous cell cancer of the head and neck;

bladder cancer;

liver cancer; or

a type of colorectal cancer that laboratory testing proves to have certain specific DNA mutations.

Opdivo is often given when the cancer has spread to other parts of the body, or cannot be surgically removed, or has come back after prior treatment.
For some types of cancer, Opdivo is given only if your tumor has a specific genetic marker (an abnormal "EGFR" or "ALK" gene).

DOSAGE.

​Unresectable or metastatic melanoma
​240 mg every 2 weeks
​(30-minute intravenous infusion)
​or
​480 mg every 4 weeks
​(30-minute intravenous infusion)
​Until disease progression or unacceptable toxicity
​Metastatic non-small cell lung cancer
​Advanced renal cell carcinoma
​Classical Hodgkin lymphoma
​Squamous cell carcinoma of the head and neck
​Urothelial carcinoma
​Hepatocellular carcinoma
​Adjuvant treatment of melanoma
​240 mg every 2 weeks
​(30-minute intravenous infusion)
​or
​480 mg every 4 weeks
​(30-minute intravenous infusion)
​Until disease recurrence or unacceptable toxicity for up to 1 year
​Small cell lung cancer
​240 mg every 2 weeks
​(30-minute intravenous infusion)
​Until disease progression or unacceptable toxicity
​Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer
​Adult patients and pediatric patients age 12 years and older and weighing 40 kg or more:
​240 mg every 2 weeks
​(30-minute intravenous infusion)
​or
​480 mg every 4 weeks
​(30-minute intravenous infusion)
​Until disease progression or unacceptable toxicity
​Pediatric patients age 12 years and older and weighing less than 40 kg:
​3 mg/kg every 2 weeks
​(30-minute intravenous infusion